STOCK TITAN

Invivyd (IVVD) Stock News, Nov 2024-Mar 2025

IVVD NASDAQ

Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.

Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.

Rhea-AI Summary

Invivyd (NASDAQ: IVVD) announced that PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the currently dominant SARS-CoV-2 variant LP.8.1. The company's in vitro data demonstrates consistent neutralization against the three most prevalent U.S. variants: LP.8.1, XEC, and KP.3.1.1, as reported by the CDC.

PEMGARDA, authorized in the U.S. for pre-exposure prophylaxis of COVID-19 in immunocompromised patients, has shown stable neutralization activity since the Omicron BA.2 lineage. The company's next-generation candidate, VYD2311, also demonstrates effective neutralization against LP.8.1.

According to ACIP data presented, immunocompromised COVID-19 patients face:

  • 2x higher likelihood of ICU admission
  • 3x greater risk of requiring mechanical ventilation
  • 4x higher hospital mortality rate
The data has been submitted to the FDA, with an anticipated update to the PEMGARDA Fact Sheet for Healthcare Providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
Rhea-AI Summary

Invivyd (NASDAQ: IVVD) announced that the FDA declined their request to expand PEMGARDA™ (pemivibart) Emergency Use Authorization (EUA) to include treatment of mild-to-moderate COVID-19 in immunocompromised patients. The FDA's decision was based on the requirement that monoclonal antibodies must demonstrate superior, rather than equivalent, antiviral activity compared to previously authorized antibodies.

The company's submission showed comparable antiviral activity between pemivibart and adintrevimab, with predicted clinical efficacy above currently authorized convalescent plasma. The existing PEMGARDA EUA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients remains unchanged.

Invivyd plans to advance VYD2311 in collaboration with FDA, addressing the ongoing COVID-19 burden. The company noted that the COVID-19 treatment opportunity for pemivibart was not included in existing financial guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.94%
Tags
fda approval covid-19
-
Rhea-AI Summary

Invivyd (Nasdaq: IVVD) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Marc Elia, Chairman of the Invivyd Board of Directors, will deliver a presentation on Wednesday, February 12th, 2025 at 1:20 PM ET.

The presentation will be accessible via live webcast through the investor section of Invivyd's website at investors.invivyd.com. The recording will remain available for approximately 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.04%
Tags
conferences
Rhea-AI Summary

Invivyd (Nasdaq: IVVD) has announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing impact of COVID-19. The initiative focuses on highlighting that COVID-19 remains a significant health concern, causing approximately one American death every 9 minutes, with about 59,000 deaths and 665,000 hospitalizations in 2024, despite widespread vaccination.

The partnership aims to educate the public, especially immunocompromised individuals such as cancer patients and organ transplant recipients, about COVID-19's short and potential long-term risks. Recent data shows increasing ICU admission rates for COVID-19 hospitalizations, and research suggests the long-term health and economic burden may exceed several other chronic diseases.

Through live and social media initiatives, Coach Harbaugh will help promote awareness and encourage people to learn more about available options beyond vaccines at www.expandtheiroptions.com. The campaign emphasizes that while COVID-19 is common, it should not be dismissed as merely a cold.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
68.80%
Tags
partnership covid-19
-
Rhea-AI Summary

Invivyd (NASDAQ: IVVD) announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed as an alternative to COVID-19 vaccination. The trial, involving 40 subjects across multiple administration routes, showed promising results in both safety and pharmacokinetics.

Key findings include:

  • Mild to moderate adverse events, mainly to injection site reactions
  • High serum concentrations maintained through Day 65
  • 17-fold greater neutralization potency compared to pemivibart
  • Potential for 70-90% protection from symptomatic COVID-19
  • Possibility of once or twice-annual dosing

The data suggests VYD2311 could offer superior efficacy, safety, and durability compared to current COVID-19 vaccines, while also serving as a potential treatment option. The company completed recruitment and dosing, with only long-term follow-up remaining.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
196.34%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Invivyd (IVVD) announced preliminary Q4 2024 financial results, showing strong growth with PEMGARDA™ net product revenue of $13.8 million, a 48% increase from Q3 2024's $9.3 million. The company significantly reduced operating costs to $32 million in Q4, down 55% from Q3's $71.6 million, primarily through manufacturing expense reductions.

The company ended 2024 with $69.3 million in cash and cash equivalents plus $10.9 million in accounts receivable. Invivyd expects minimal manufacturing expenses in 2025, as VYD2311 commercial manufacturing was completed in 2024 to support up to one million doses. The company maintains its target for near-term profitability by the end of 1H 2025, supported by existing cash, anticipated revenue growth, and continued cost reductions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
196.34%
Tags
Rhea-AI Summary

Invivyd (NASDAQ: IVVD) has submitted an updated immunobridging analysis to the FDA supporting its request to expand PEMGARDA™ (pemivibart) Emergency Use Authorization (EUA) to include treatment of mild-to-moderate COVID-19 in certain immunocompromised patients. The analysis demonstrates that pemivibart shows substantially higher antiviral titers in the early phase post-dosing compared to adintrevimab, which previously showed 66-74% reduction in hospitalization or death risk.

PEMGARDA received initial EUA in March 2024 for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals. The updated analysis incorporates data from the dominant SARS-CoV-2 variant XEC and builds upon multiple analyses submitted since July 2024. Notably, no additional anaphylaxis cases have been reported during post-authorization use, following the four cases observed in the CANOPY Phase 3 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.85%
Tags
fda approval covid-19
-
Rhea-AI Summary

Invivyd (NASDAQ: IVVD) announced new in vitro neutralization data demonstrating continued effectiveness of PEMGARDA™ (pemivibart) against the dominant SARS-CoV-2 variant XEC. The data shows consistent neutralizing activity, similar to previously reported results for KP.3.1.1. According to CDC estimates, XEC and KP.3.1.1 together represented 69% of U.S. circulating variants as of December 21, 2024.

PEMGARDA has demonstrated positive neutralization activity against over 75% of currently circulating U.S. variants and all prior variants tested. The company has submitted these new data to the FDA, with an expected update to the PEMGARDA Fact Sheet for Healthcare Providers. The drug has shown antiviral activity against 39 distinct SARS-CoV-2 variants over almost three years of virus evolution, with minimal changes in neutralization activity compared to predecessor medicines like Evusheld™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Summary

Invivyd reported Q3 2024 financial results with PEMGARDA™ net product revenue of $9.3 million, up from $2.3 million in Q2 2024. The company ended Q3 with $106.9 million in cash and expects to end 2024 with at least $65 million. The quarter saw a net loss of $60.7 million ($0.51 per share). R&D expenses increased to $57.9 million, while SG&A expenses remained stable at $13.0 million. The PEMGARDA Fact Sheet was updated to reflect neutralization activity against current COVID-19 variants, including KP.3, KP.3.1.1, and LB.1. The company initiated Phase 1 trials for VYD2311, their next-generation COVID-19 antibody.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
Rhea-AI Summary

The New England Journal of Medicine (NEJM) published a Letter to the Editor describing PEMGARDA™ (pemivibart)'s immunobridging emergency use authorization pathway and an updated correlate of protection curve for COVID-19 prevention. The letter highlights the FDA-designed approach for rapid development of monoclonal antibodies against evolving COVID-19 variants. Invivyd expressed disappointment regarding a separate NEJM letter from Columbia University's Ho Lab containing discordant data about pemivibart's effectiveness against KP.3.1.1 variant. The FDA maintains that PEMGARDA likely retains adequate neutralization activity against current U.S. SARS-CoV-2 variants, including KP.3.1.1, LB.1, KP.3, and KP.2.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
none

FAQ

What is the current stock price of Invivyd (IVVD)?

Invivyd (IVVD) last closed at $0.5377.

What is the market cap of Invivyd (IVVD)?

The market cap of Invivyd (IVVD) is approximately $158.5M.